{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Register low-grade muzinöse\nNeoplasien der Appendix (LAMN)

","eudractNumber":null,"id":8732,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-04-14T09:42:07+02:00","shortTitle":"LAMN-Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with with primary high-risk lobular breast cancer - LOBSTER","eudractNumber":"2023-509292-17-00","id":9924,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06607757","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-11T12:09:43+01:00","shortTitle":"LOBSTER","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"Liquid Biopsy als Biomarker unter PSMA-Radioligandentherapie","eudractNumber":null,"id":11461,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07118436","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-05-01T09:40:08+02:00","shortTitle":"LOOPS","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib\n(LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in\nPreviously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma\n(BRUIN CLL-322)

","eudractNumber":"2021-000043-49","id":9343,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04965493","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-02-02T11:43:44+01:00","shortTitle":"LOXO-BTK-20022","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Data collection to design and validate LEOPARD predictive models of delisting in liver transplant candidates","eudractNumber":null,"id":11696,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06675604","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2026-03-01T12:08:50+01:00","shortTitle":"Leopard","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospektive NIS zu klinischen Outcomes bei Patienten mit fortgeschrittenem nicht kleinzelligem Lungenkrebs (NSCLC) mit EGFR Mutation unter Behandlung mit zugelassenem Amivantamab-haltigen Therapieschemata im Rahmen der standardmäßigen klinischen Praxis","eudractNumber":null,"id":11841,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T11:41:58+01:00","shortTitle":"Lepidoptera","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Krebsassoziierte Fatigue: Wissen, Einstellungen, Bedürfnisse und aktueller Stand der Fatigue-Versorgung in Deutschland
VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":7915,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-04-01T11:30:20+02:00","shortTitle":"LiFT- Projekt","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Registerstudie zur Ätiologie, biologischem\nErkrankungsprofil und klinischem Verlauf bei „Low grade“-Gliomen: die\nLoG-Glio-Epidemiologie und Outcome-Studie (LoG-Glio)

","eudractNumber":null,"id":2611,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02686229","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2017-01-15T13:46:52+01:00","shortTitle":"LoG-Glio","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive. A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer.
","eudractNumber":"2024-519773-19","id":11702,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06901531","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-16T11:09:29+02:00","shortTitle":"Lucerna","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

Histologische, immunphänotypische und molekulargenetische\nCharakterisierung kutaner\nLymphom

","eudractNumber":null,"id":2695,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-10-14T09:41:37+02:00","shortTitle":"Lymphomsequenzierung","therapeutical":false,"therapyLines":[]}]}